890 results on '"Mok, T."'
Search Results
2. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology
3. The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective
4. Electrical tunability due to coalescence of exceptional points in parity-time symmetric waveguides
5. Anomalous Light Scattering by Topological ${\mathcal{PT}}$-symmetric Particle Arrays
6. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series
7. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
8. P2.06-05 Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON
9. P2.09-17 OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small Cell Lung Cancer
10. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
11. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
12. PP01.47 HERTHENA-Lung02: A Randomized Phase 3 Study of Patritumab Deruxtecan vs Platinum-Based Chemotherapy in Locally Advanced or Metastatic EGFR-Mutated NSCLC After Progression with a Third-Generation EGFR TKI
13. Durvalumab (D)+/− tremelimumab (T)+chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
14. Assoziation von KRAS/STK11/KEAP1 Mutationen und Outcome in der POSEIDON Studie: Durvalumab+/− Tremelimumab+Chemotherapie beim metastasierten NSCLC (mNSCLC)
15. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
16. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
17. EP08.01-042 NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC
18. OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
19. MA13.03 Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies
20. EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
21. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
22. Supplement to: Osimertinib or platinum—pemetrexed in EGFR T790M—positive lung cancer.
23. Supplement to: Variant Creutzfeldt-Jakob disease in a patient with heterozygosity at PRNP codon 129.
24. Overview of current systemic management of EGFR-mutant NSCLC
25. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
26. Durvalumab +/− Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase III POSEIDON Study
27. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
28. Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking
29. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
30. Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study
31. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
32. Supplement to: First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
33. PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
34. Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042: 195TiP
35. NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC: 192TiP
36. LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations: 140PD
37. Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials: 141PD
38. Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6): 138PD
39. Being molecular in the molecular age
40. Corrigendum to 'Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)' [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978] (Critical Reviews in Oncology / Hematology (2020) 151, (S1040842820301165), (10.1016/j.critrevonc.2020.102978))
41. Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
42. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
43. Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Patients with Surgically Resected Non-Small Cell Lung Cancer: CANOPY-N Trial
44. Accuracy of automated three‐dimensional ultrasound imaging technique for fetal head biometry
45. P76.78 Evaluation of the Development of Brain Metastases in Patients Treated with Dacomitinib or Gefitinib from ARCHER 1050 Study
46. P35.15 Molecular Epidemiology of KRAS G12C Mutations in Chinese Lung Cancer Patients
47. P03.05 CANOPY-N: Neoadjuvant Canakinumab and Pembrolizumab in Patients With Surgically Resectable Non-Small Cell Lung Cancer
48. P76.67 Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
49. FP14.12 Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3.
50. MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.